EULAR 2022 Brochur LF

EULAR 2002
Congress Preview
Lupus
Chair’s Introduction
Dear Colleagues,
Welcome to the Lupus Forum EULAR 2022 Congress Preview. This pre-congress brochure provides you with all you need to know
about the lupus content at EULAR this year, including the plenaries, posters, and Chair’s picks of the content that you shouldn’t miss.
Poster Views on Wednesday include safety data for belimumab (POS0712), baricitinib (POS0714), and rituximab (POS1320),
the hypersensitivity profile of anifrolumab (POS0708) and data on BICLA and BILAG organ domain responses in patients receiving
anifrolumab (POS0709), among others.
Thursday morning sees the What’s New In session focus on systemic lupus erythematosus, with Professor Thomas Dörner
presenting “From pathogenesis to new therapies”.
A Clinical Science Plenary on Friday spotlights joint and skin involvement in SLE, with the Lupus Forum’s Dr Victoria Werth and
myself presenting, alongside Professor Annamaria Iagnocco. Also on Friday, there are oral abstract presentations in the Recent
Novelties in SLE/Sjogren and APS session on voclosporin efficacy in achieving proteinuria treatment targets in lupus nephritis
(OP0285), and the pharmocodynamic effect of sequential belimumab and rituximab (OP0281).
It’s worth taking the opportunity to explore the Posters on Friday, with interesting submissions on voclosporin for lupus nephritis
(POS0186), Phase 3 data on efficacy and safety of baricitinib in SLE (POS0190), the effect of belimumab on SRI-4 response
(POS0183), and atacicept impact on renal function (POS0189), both in SLE.
Saturday sees a dedicated poster tour, Systemic Lupus Erythematosus: Monitoring and Management, with many posters of interest.
I’d like to draw your attention to two in particular, focusing on SLE and the improvement of mucocutaneous manifestations in
patients treated with anifrolumab (POS0367), and early improvement in physician global assessment as a predictor of long-term
retention of belimumab treatment (POS0368).
We add new content to the Lupus Forum regularly, with monthly slide summaries of key publications, podcasts discussing recent
advances, and congress materials like these. You can register for updates at lupus-forum.com or keep up to date by following us on
Twitter @LupusForum and on LinkedIn by searching “Lupus Forum”.
However you choose to attend EULAR 2022, whether in person or virtually, I hope you find our selection of highlights useful and that
you enjoy the meeting.
Kind regards,
Ed Vital
Associate Professor, University of Leeds
Key Lupus Content
Wednesday, 01 June 2022
Chairman’s Picks
All day Poster View 4
POS0705
POS0707
POS0708
POS0709
POS0712
POS0714
POS0719
Dilemma of Belimumab Therapy (Dis)Continuation During Pregnancy: Results of a Retrospective Study in EudraVigilance
Nafise Ghalandari
Potential Use of Belimumab in Lupus Patients from Argentine Cohort According Disease Activity State
Rosana Quintana
Evaluating the Hypersensitivity Profile of Anifrolumab and the Need for Preinfusion Prophylactic Treatment in Patients with SLE
Kenneth C Kalunian
Sustained BICLA and BILAG Organ Domain Responses in Patients with Systemic Lupus Erythematosus (SLE) Receiving
Anifrolumab in Two Phase 3 Trials
Ronald van Vollenhoven
Year-4 Observational Follow-Up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE who Completed a
Phase 4, 52-Week, Randomised, Double-Blind Placebo-Controlled Safety Study
Saira Sheikh
Pooled Safety Analysis of Baricitinib in Patients with Systemic Lupus Erythematosus: Results from Three Randomised,
Double-Blind, Placebo-Controlled, Clinical Trials
Thomas Dörner
Rapid Efficacy of Anifrolumab in Multiple Subtypes of Recalcitrant Cutaneous Lupus Parallels Discrete Changes in
Transcriptomic and Cellular Biomarkers
Lucy Marie Carter
All day Poster View 10
POS1320
Safety And Efficacy of Rituximab in Patients with Juvenile Systemic Lupus Erythematosus: The Preliminary Data of
Retrospective Cohort Study
Rinat Raupov

Chairman’s Picks
Thursday, 02 June 2022
10:30–
11:07
What’s New In
Systemic Lupus Erythematosus
From Pathogenesis to New Therapies: What is New in SLE?
Thomas Dörner
Friday, 03 June 2022
13:30–
14:45
10:30 –
12:00
OP0281
OP0285
12:00–
13:30
POS0183
POS0186
POS0189
POS0190
Clinical Science Session
Joint and Skin Involvement in SLE
Therapeutic Algorithms to Treat Cutaneous Lupus: What is New?
Victoria Werth
The Role of Imaging in the Assessment of Joint Involvement in SLE
Annamaria Iagnocco
Joint Involvement in SLE: Clinical Assessment, Role of Biomarkers and New Therapeutic Options
Edward Vital
Oral Abstract Presentation Session
Recent Novelties in SLE/Sjogren and APS
Pharmacodynamic Effect of Sequential Belimumab (BEL) and Rituximab (RTX) Therapy in Patients (Pts) with Systemic
Lupus Erythematosus (SLE): The Phase 3, Randomised, Placebo-Controlled BLISS-BELIEVE Study
Y.K. Onno Teng
Voclosporin is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
Hans-Joachim Anders
Poster View Auditorium 7
New Options in SLE-Sjogren and APS
The Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with Systemic Lupus Erythematosus:
Results of a Large Integrated Analysis
George Bertsias
Voclosporin for Lupus Nephritis: Results of the Two-year AURORA 2 Continuation Study
Amit Saxena
Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)
David Isenberg
Efficacy and Safety of Baricitinib in Patients with Systemic Lupus Erythematosus: Results from Two Randomised,
Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Studies
Eric F. Morand
Saturday, 04 June 2022
10:15–
11:45
POS0367
POS0368
Poster View Auditorium 10
Systemic Lupus Erythematosus: Monitoring and Management
Improvement of Individual Mucocutaneous Manifestations in Patients with Systemic Lupus Erythematosus Treated
with Anifrolumab
Victoria Werth
Early (3 Months) Improvement in Physician Global Assessment of Disease Activity Predicts Long-Term Retention of
Belimumab Treatment in SLE: A Multicentre Observational Study of 184 Patients
George Bertsias
Developed
under the
auspices of:
Supported with
an educational
grant from: